Genome-wide mutational analyses have revealed somatic mutations in the cytosolic NADP+-dependent isocitrate dehydrogenase 1 (IDH1) in 12% of glioblastoma multiforme (GBM) patients [1]. This evidence concerns the gene IDH1 and glioblastoma.